|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:RANBP2-ALK (FusionGDB2 ID:HG5903TG238) |
Fusion Gene Summary for RANBP2-ALK |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: RANBP2-ALK | Fusion gene ID: hg5903tg238 | Hgene | Tgene | Gene symbol | RANBP2 | ALK | Gene ID | 5903 | 238 |
| Gene name | RAN binding protein 2 | ALK receptor tyrosine kinase | |
| Synonyms | ADANE|ANE1|IIAE3|NUP358|TRP1|TRP2 | CD246|NBLST3 | |
| Cytomap | ('RANBP2')('ALK') 2q13 | 2p23.2-p23.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | E3 SUMO-protein ligase RanBP2358 kDa nucleoporinE3 SUMO-protein transferase RanBP2P270acute necrotizing encephalopathy 1 (autosomal dominant)nuclear pore complex protein Nup358nucleoporin 358nucleoporin Nup358ran-binding protein 2transformation-r | ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | P49792 | Q9UM73 | |
| Ensembl transtripts involved in fusion gene | ENST00000283195, | ||
| Fusion gene scores | * DoF score | 20 X 18 X 8=2880 | 56 X 74 X 20=82880 |
| # samples | 21 | 57 | |
| ** MAII score | log2(21/2880*10)=-3.77760757866355 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(57/82880*10)=-7.18391827352181 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: RANBP2 [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | |||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RANBP2 | GO:0016925 | protein sumoylation | 17264123|22155184 |
| Tgene | ALK | GO:0016310 | phosphorylation | 9174053 |
| Tgene | ALK | GO:0046777 | protein autophosphorylation | 9174053 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerKB3 | . | . | RANBP2 | chr2 | 109375004 | + | ALK | chr2 | 29446394 | - |
Top |
Fusion Gene ORF analysis for RANBP2-ALK |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000283195 | ENST00000431873 | RANBP2 | chr2 | 109375004 | + | ALK | chr2 | 29446394 | - |
| 5CDS-intron | ENST00000283195 | ENST00000498037 | RANBP2 | chr2 | 109375004 | + | ALK | chr2 | 29446394 | - |
| In-frame | ENST00000283195 | ENST00000389048 | RANBP2 | chr2 | 109375004 | + | ALK | chr2 | 29446394 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000283195 | RANBP2 | chr2 | 109375004 | + | ENST00000389048 | ALK | chr2 | 29446394 | - | 4869 | 2728 | 27 | 4418 | 1463 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for RANBP2-ALK |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for RANBP2-ALK |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:/chr2:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| RANBP2 | ALK |
| FUNCTION: E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I (PubMed:11792325, PubMed:12032081, PubMed:15378033, PubMed:22194619, PubMed:15931224). Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates (PubMed:7775481). Binds single-stranded RNA (in vitro) (PubMed:7775481). May bind DNA (PubMed:7775481). Component of the nuclear export pathway (PubMed:10078529). Specific docking site for the nuclear export factor exportin-1 (PubMed:10078529). Sumoylates PML at 'Lys-490' which is essential for the proper assembly of PML-NB (PubMed:22155184). Recruits BICD2 to the nuclear envelope and cytoplasmic stacks of nuclear pore complex known as annulate lamellae during G2 phase of cell cycle (PubMed:20386726). Probable inactive PPIase with no peptidyl-prolyl cis-trans isomerase activity (PubMed:20676357, PubMed:23353830). {ECO:0000269|PubMed:11792325, ECO:0000269|PubMed:12032081, ECO:0000269|PubMed:15378033, ECO:0000269|PubMed:15931224, ECO:0000269|PubMed:20386726, ECO:0000269|PubMed:20676357, ECO:0000269|PubMed:22155184, ECO:0000269|PubMed:22194619, ECO:0000269|PubMed:23353830, ECO:0000269|PubMed:7775481, ECO:0000303|PubMed:10078529}. | FUNCTION: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. Thinness gene involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). {ECO:0000250|UniProtKB:P97793, ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15908427, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for RANBP2-ALK |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >72053_72053_1_RANBP2-ALK_RANBP2_chr2_109375004_ENST00000283195_ALK_chr2_29446394_ENST00000389048_length(transcript)=4869nt_BP=2728nt CACAGTGGTCCTCCGCCGGCTACGGCGCTGCGTCACTGGTTTGCAGGCGCTTTCCTCTTGGAAGTGGCGACTGCTGCGGGCCTGAGCGCT GGTCTCACGCGCCTCGGGAGCCAGGTTGGCGGCGCGATGAGGCGCAGCAAGGCTGACGTGGAGCGGTACATCGCCTCGGTGCAGGGCTCC ACCCCGTCGCCTCGACAGAAGTCAATGAAAGGATTCTATTTTGCAAAGCTGTATTATGAAGCTAAAGAATATGATCTTGCTAAAAAATAC ATATGTACTTACATTAATGTGCAAGAGAGGGATCCCAAAGCTCACAGATTTCTGGGTCTTCTTTATGAATTGGAAGAAAACACAGACAAA GCCGTTGAATGTTACAGGCGTTCAGTGGAATTAAACCCAACACAAAAAGATCTTGTGTTGAAGATTGCAGAATTGCTTTGTAAAAATGAT GTTACTGATGGAAGAGCAAAATACTGGCTTGAAAGAGCAGCCAAACTTTTCCCAGGAAGTCCTGCAATTTATAAACTAAAGGAACAGCTT CTAGATTGTGAAGGTGAAGATGGATGGAATAAACTTTTTGACTTGATTCAGTCAGAACTTTATGTAAGACCTGATGACGTCCATGTGAAC ATCCGGCTAGTGGAGGTGTATCGCTCAACTAAAAGATTGAAGGATGCTGTGGCCCACTGCCATGAGGCAGAGAGGAACATAGCTTTGCGT TCAAGTTTAGAATGGAATTCGTGTGTTGTACAGACCCTTAAGGAATATCTGGAGTCTTTACAGTGTTTGGAGTCTGATAAAAGTGACTGG CGAGCAACCAATACAGACTTACTGCTGGCCTATGCTAATCTTATGCTTCTTACGCTTTCCACTAGAGATGTGCAGGAAAGTAGAGAATTA CTGCAAAGTTTTGATAGTGCTCTTCAGTCTGTGAAATCTTTGGGTGGAAATGATGAACTGTCAGCTACTTTCTTAGAAATGAAAGGACAT TTCTACATGCATGCTGGTTCTCTGCTTTTGAAGATGGGTCAGCATAGTAGTAATGTTCAATGGCGAGCTCTTTCTGAGCTGGCTGCATTG TGCTATCTCATAGCATTTCAGGTTCCAAGACCAAAGATTAAATTAATAAAAGGTGAAGCTGGACAAAATCTGCTGGAAATGATGGCCTGT GACCGACTGAGCCAATCAGGGCACATGTTGCTAAACTTAAGTCGTGGCAAGCAAGATTTTTTAAAAGAGATTGTTGAAACTTTTGCCAAC AAAAGCGGGCAGTCTGCATTATATGATGCTCTGTTTTCTAGTCAGTCACCTAAGGATACATCTTTTCTTGGTAGCGATGATATTGGAAAC ATTGATGTACGAGAACCAGAGCTTGAAGATTTGACTAGATACGATGTTGGTGCTATTCGAGCACATAATGGTAGTCTTCAGCACCTTACT TGGCTTGGCTTACAGTGGAATTCATTGCCTGCTTTACCTGGAATCCGAAAATGGCTAAAACAGCTTTTCCATCATTTGCCCCATGAAACC TCAAGGCTTGAAACAAATGCACCTGAATCAATATGTATTTTAGATCTTGAAGTATTTCTCCTTGGAGTAGTATATACCAGCCACTTACAA TTAAAGGAGAAATGTAATTCTCACCACAGCTCCTATCAGCCGTTATGCCTGCCCCTTCCTGTGTGTAAACAGCTTTGTACAGAAAGACAA AAATCTTGGTGGGATGCGGTTTGTACTCTGATTCACAGAAAAGCAGTACCTGGAAACGTAGCAAAATTGAGACTTCTAGTTCAGCATGAA ATAAACACTCTAAGAGCCCAGGAAAAACATGGCCTTCAACCTGCTCTGCTTGTACATTGGGCAGAATGCCTTCAGAAAACGGGCAGCGGT CTTAATTCTTTTTATGATCAACGAGAATACATAGGGAGAAGTGTTCATTATTGGAAGAAAGTTTTGCCATTGTTGAAGATAATAAAAAAG AAGAACAGTATTCCTGAACCTATTGATCCTCTGTTTAAACATTTTCATAGTGTAGACATTCAGGCATCAGAAATTGTTGAATATGAAGAA GACGCACACATAACTTTTGCTATATTGGATGCAGTAAATGGAAATATAGAAGATGCTGTGACTGCTTTTGAATCTATAAAAAGTGTTGTT TCTTATTGGAATCTTGCACTGATTTTTCACAGGAAGGCAGAAGACATTGAAAATGATGCCCTTTCTCCTGAAGAACAAGAAGAATGCAAA AATTATCTGAGAAAGACCAGGGACTACCTAATAAAGATTATAGATGACAGTGATTCAAATCTTTCAGTGGTCAAGAAATTGCCTGTGCCC CTGGAGTCTGTAAAAGAGATGCTTAATTCAGTCATGCAGGAACTCGAAGACTATAGTGAAGGAGGTCCTCTCTATAAAAATGGTTCTTTG CGAAATGCAGATTCAGAAATAAAACATTCTACACCGTCTCCTACCAGATATTCACTATCACCAAGTAAAAGTTACAAGTATTCTCCCAAA ACACCACCTCGATGGGCAGAAGATCAGAATTCTTTACTGAAAATGATTTGCCAACAAGTAGAGGCCATTAAGAAAGAAATGCAGGAGTTG AAACTAAATAGCAGTAACTCAGCATCCCCTCATCGTTGGCCCACAGAGAATTATGGACCAGACTCAGTGCCTGATGGATATCAGGGGTCA CAGACATTTCATGGGGCTCCACTAACAGTGTACCGCCGGAAGCACCAGGAGCTGCAAGCCATGCAGATGGAGCTGCAGAGCCCTGAGTAC AAGCTGAGCAAGCTCCGCACCTCGACCATCATGACCGACTACAACCCCAACTACTGCTTTGCTGGCAAGACCTCCTCCATCAGTGACCTG AAGGAGGTGCCGCGGAAAAACATCACCCTCATTCGGGGTCTGGGCCATGGCGCCTTTGGGGAGGTGTATGAAGGCCAGGTGTCCGGAATG CCCAACGACCCAAGCCCCCTGCAAGTGGCTGTGAAGACGCTGCCTGAAGTGTGCTCTGAACAGGACGAACTGGATTTCCTCATGGAAGCC CTGATCATCAGCAAATTCAACCACCAGAACATTGTTCGCTGCATTGGGGTGAGCCTGCAATCCCTGCCCCGGTTCATCCTGCTGGAGCTC ATGGCGGGGGGAGACCTCAAGTCCTTCCTCCGAGAGACCCGCCCTCGCCCGAGCCAGCCCTCCTCCCTGGCCATGCTGGACCTTCTGCAC GTGGCTCGGGACATTGCCTGTGGCTGTCAGTATTTGGAGGAAAACCACTTCATCCACCGAGACATTGCTGCCAGAAACTGCCTCTTGACC TGTCCAGGCCCTGGAAGAGTGGCCAAGATTGGAGACTTCGGGATGGCCCGAGACATCTACAGGGCGAGCTACTATAGAAAGGGAGGCTGT GCCATGCTGCCAGTTAAGTGGATGCCCCCAGAGGCCTTCATGGAAGGAATATTCACTTCTAAAACAGACACATGGTCCTTTGGAGTGCTG CTATGGGAAATCTTTTCTCTTGGATATATGCCATACCCCAGCAAAAGCAACCAGGAAGTTCTGGAGTTTGTCACCAGTGGAGGCCGGATG GACCCACCCAAGAACTGCCCTGGGCCTGTATACCGGATAATGACTCAGTGCTGGCAACATCAGCCTGAAGACAGGCCCAACTTTGCCATC ATTTTGGAGAGGATTGAATACTGCACCCAGGACCCGGATGTAATCAACACCGCTTTGCCGATAGAATATGGTCCACTTGTGGAAGAGGAA GAGAAAGTGCCTGTGAGGCCCAAGGACCCTGAGGGGGTTCCTCCTCTCCTGGTCTCTCAACAGGCAAAACGGGAGGAGGAGCGCAGCCCA GCTGCCCCACCACCTCTGCCTACCACCTCCTCTGGCAAGGCTGCAAAGAAACCCACAGCTGCAGAGATCTCTGTTCGAGTCCCTAGAGGG CCGGCCGTGGAAGGGGGACACGTGAATATGGCATTCTCTCAGTCCAACCCTCCTTCGGAGTTGCACAAGGTCCACGGATCCAGAAACAAG CCCACCAGCTTGTGGAACCCAACGTACGGCTCCTGGTTTACAGAGAAACCCACCAAAAAGAATAATCCTATAGCAAAGAAGGAGCCACAC GACAGGGGTAACCTGGGGCTGGAGGGAAGCTGTACTGTCCCACCTAACGTTGCAACTGGGAGACTTCCGGGGGCCTCACTGCTCCTAGAG CCCTCTTCGCTGACTGCCAATATGAAGGAGGTACCTCTGTTCAGGCTACGTCACTTCCCTTGTGGGAATGTCAATTACGGCTACCAGCAA CAGGGCTTGCCCTTAGAAGCCGCTACTGCCCCTGGAGCTGGTCATTACGAGGATACCATTCTGAAAAGCAAGAATAGCATGAACCAGCCT GGGCCCTGAGCTCGGTCGCACACTCACTTCTCTTCCTTGGGATCCCTAAGACCGTGGAGGAGAGAGAGGCAATGGCTCCTTCACAAACCA GAGACCAAATGTCACGTTTTGTTTTGTGCCAACCTATTTTGAAGTACCACCAAAAAAGCTGTATTTTGAAAATGCTTTAGAAAGGTTTTG AGCATGGGTTCATCCTATTCTTTCGAAAGAAGAAAATATCATAAAAATGAGTGATAAATACAAGGCCCAGATGTGGTTGCATAAGGTTTT TATGCATGTTTGTTGTATACTTCCTTATGCTTCTTTCAAATTGTGTGTGCTCTGCTTCAATGTAGTCAGAATTAGCTGCTTCTATGTTTC ATAGTTGGGGTCATAGATGTTTCCTTGCCTTGTTGATGTGGACATGAGCCATTTGAGGGGAGAGGGAACGGAAATAAAGGAGTTATTTGT >72053_72053_1_RANBP2-ALK_RANBP2_chr2_109375004_ENST00000283195_ALK_chr2_29446394_ENST00000389048_length(amino acids)=1463AA_BP=900 MRHWFAGAFLLEVATAAGLSAGLTRLGSQVGGAMRRSKADVERYIASVQGSTPSPRQKSMKGFYFAKLYYEAKEYDLAKKYICTYINVQE RDPKAHRFLGLLYELEENTDKAVECYRRSVELNPTQKDLVLKIAELLCKNDVTDGRAKYWLERAAKLFPGSPAIYKLKEQLLDCEGEDGW NKLFDLIQSELYVRPDDVHVNIRLVEVYRSTKRLKDAVAHCHEAERNIALRSSLEWNSCVVQTLKEYLESLQCLESDKSDWRATNTDLLL AYANLMLLTLSTRDVQESRELLQSFDSALQSVKSLGGNDELSATFLEMKGHFYMHAGSLLLKMGQHSSNVQWRALSELAALCYLIAFQVP RPKIKLIKGEAGQNLLEMMACDRLSQSGHMLLNLSRGKQDFLKEIVETFANKSGQSALYDALFSSQSPKDTSFLGSDDIGNIDVREPELE DLTRYDVGAIRAHNGSLQHLTWLGLQWNSLPALPGIRKWLKQLFHHLPHETSRLETNAPESICILDLEVFLLGVVYTSHLQLKEKCNSHH SSYQPLCLPLPVCKQLCTERQKSWWDAVCTLIHRKAVPGNVAKLRLLVQHEINTLRAQEKHGLQPALLVHWAECLQKTGSGLNSFYDQRE YIGRSVHYWKKVLPLLKIIKKKNSIPEPIDPLFKHFHSVDIQASEIVEYEEDAHITFAILDAVNGNIEDAVTAFESIKSVVSYWNLALIF HRKAEDIENDALSPEEQEECKNYLRKTRDYLIKIIDDSDSNLSVVKKLPVPLESVKEMLNSVMQELEDYSEGGPLYKNGSLRNADSEIKH STPSPTRYSLSPSKSYKYSPKTPPRWAEDQNSLLKMICQQVEAIKKEMQELKLNSSNSASPHRWPTENYGPDSVPDGYQGSQTFHGAPLT VYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQV AVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGC QYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGY MPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKD PEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTY GSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAAT -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for RANBP2-ALK |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for RANBP2-ALK |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | ALK | Q9UM73 | DB08865 | Crizotinib | Inhibitor | Small molecule | Approved |
| Tgene | ALK | Q9UM73 | DB09063 | Ceritinib | Antagonist | Small molecule | Approved |
| Tgene | ALK | Q9UM73 | DB11363 | Alectinib | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ALK | Q9UM73 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ALK | Q9UM73 | DB12130 | Lorlatinib | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ALK | Q9UM73 | DB12141 | Gilteritinib | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ALK | Q9UM73 | DB12267 | Brigatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for RANBP2-ALK |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | RANBP2 | C2675556 | ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 3 | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | RANBP2 | C0334121 | Inflammatory Myofibroblastic Tumor | 2 | CTD_human;ORPHANET |
| Hgene | RANBP2 | C0018199 | Granuloma, Plasma Cell | 1 | CTD_human |
| Hgene | RANBP2 | C4706387 | Acute necrotizing encephalopathy of childhood | 1 | ORPHANET |
| Tgene | C0007131 | Non-Small Cell Lung Carcinoma | 28 | CGI;CTD_human | |
| Tgene | C0027819 | Neuroblastoma | 13 | CGI;CTD_human;ORPHANET | |
| Tgene | C0152013 | Adenocarcinoma of lung (disorder) | 8 | CGI;CTD_human | |
| Tgene | C2751681 | NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 | 8 | CLINGEN;UNIPROT | |
| Tgene | C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 6 | CGI;CTD_human | |
| Tgene | C0334121 | Inflammatory Myofibroblastic Tumor | 4 | CGI;CTD_human;ORPHANET | |
| Tgene | C0018199 | Granuloma, Plasma Cell | 3 | CTD_human | |
| Tgene | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human | |
| Tgene | C0027627 | Neoplasm Metastasis | 2 | CTD_human | |
| Tgene | C0238463 | Papillary thyroid carcinoma | 2 | ORPHANET | |
| Tgene | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET | |
| Tgene | C0006118 | Brain Neoplasms | 1 | CGI;CTD_human | |
| Tgene | C0006142 | Malignant neoplasm of breast | 1 | CTD_human | |
| Tgene | C0007134 | Renal Cell Carcinoma | 1 | CTD_human | |
| Tgene | C0011570 | Mental Depression | 1 | PSYGENET | |
| Tgene | C0011581 | Depressive disorder | 1 | PSYGENET | |
| Tgene | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human | |
| Tgene | C0036341 | Schizophrenia | 1 | PSYGENET | |
| Tgene | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human | |
| Tgene | C0085269 | Plasma Cell Granuloma, Pulmonary | 1 | CTD_human | |
| Tgene | C0153633 | Malignant neoplasm of brain | 1 | CGI;CTD_human | |
| Tgene | C0278601 | Inflammatory Breast Carcinoma | 1 | CTD_human | |
| Tgene | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human | |
| Tgene | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human | |
| Tgene | C0678222 | Breast Carcinoma | 1 | CTD_human | |
| Tgene | C0750974 | Brain Tumor, Primary | 1 | CTD_human | |
| Tgene | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human | |
| Tgene | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human | |
| Tgene | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human | |
| Tgene | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human | |
| Tgene | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human | |
| Tgene | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human | |
| Tgene | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human | |
| Tgene | C1332079 | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | ORPHANET | |
| Tgene | C1458155 | Mammary Neoplasms | 1 | CTD_human | |
| Tgene | C1527390 | Neoplasms, Intracranial | 1 | CTD_human | |
| Tgene | C2931189 | Neural crest tumor | 1 | ORPHANET | |
| Tgene | C3899155 | hereditary neuroblastoma | 1 | GENOMICS_ENGLAND | |
| Tgene | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies